AIM ImmunoTech (AIM) Net Equity Issued and Repurchased (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Net Equity Issued and Repurchased came in at $2.0 million in Q1 2026, up 203.18% YoY from $660000.0 in Q1 2025, and up 1970.09% on a QoQ basis from -$107000.0 in Q4 2025.
AIM ImmunoTech (AIM) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 16 years of Net Equity Issued and Repurchased data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 203.18% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 28.43% YoY) and the FY2025 annual result came in at $260000.0, down 59.99% from the prior year.
- Net Equity Issued and Repurchased advanced to $2.0 million in Q1 2026, from -$107000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $2.0 million in Q1 2026 to a low of -$398000.0 in Q3 2025.
- A 5-year average of $334065.4 and a median of $126000.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 10440.0% in 2024, down 242.91% in 2024.
- Tracing AIM's Net Equity Issued and Repurchased over 5 years: stood at $25000.0 in 2022, then soared by 488.0% to $147000.0 in 2023, then slumped by 242.91% to -$210084.0 in 2024, then surged by 49.07% to -$107000.0 in 2025, then surged by 1970.09% to $2.0 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $2.0 million (Q1 2026), -$107000.0 (Q4 2025), and -$398000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 537,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 537,000.00 |
| Jun 30, 2026 | 537,000.00 |
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | -107,000.00 |
| Dec 31, 2025 | -107,000.00 |
| Sep 30, 2025 | -398,000.00 |
| Sep 30, 2025 | -398,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Dec 31, 2024 | -210,084.00 |
| Dec 31, 2024 | -210,084.00 |
| Sep 30, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 527,000.00 |
| Jun 30, 2024 | 527,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Mar 31, 2024 | 329,000.00 |